Dicer increases the indication for trastuzumab treatment in gastric cancer patients via overexpression of human epidermal growth factor receptor 2

The low proportion of gastric cancer (GC) patients with high HER2 expression limits the clinical application of trastuzumab, a humanized epidermal growth factor receptor 2 (HER2) antibody targeting for GC treatment. We found that Dicer was positively correlated with HER2 expression in GC tissue by i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jianhua, Zhao, Qun, Zhao, Yue, Zhang, Xiaoyun, Tian, Yuan, Guo, Zhanjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997953/
https://www.ncbi.nlm.nih.gov/pubmed/33772068
http://dx.doi.org/10.1038/s41598-021-86485-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997953/
https://www.ncbi.nlm.nih.gov/pubmed/33772068
http://dx.doi.org/10.1038/s41598-021-86485-8

Ejemplares similares